ReviewCurrent pain and headache reports2024
Pharmacological Treatment of Fibromyalgia Syndrome: A Practice-Based Review.
Review in Current pain and headache reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Drug treatments for fibromyalgia: systematic review and network meta-analysis of randomised trials.BMJ medicine · 2026Pooled it
- Efficacy of Low-Dose Naltrexone in Women With Fibromyalgia Syndrome: A 12-Month Randomised, Double-Blind, Placebo-Controlled Single-Centre Clinical Trial (INNOVA Study).European journal of pain (London, England) · 2026Trial
- Home-based postural exercise as an adjunct to duloxetine improves sleep quality, physical quality of life, and trunk mobility in fibromyalgia: a randomized controlled trial.Rheumatology international · 2026Trial
- Article
- IgG Glycosylation Patterns May Identify Distinct Clinical Trajectories in Fibromyalgia Patients: A Longitudinal Pilot Study.European journal of pain (London, England) · 2026Article
- Therapeutic and research frontiers in fibromyalgia: integrating pathophysiology with innovative drug repurposing.Inflammopharmacology · 2026Review
- Fibromyalgia: A Multifactorial Pain Disorder.International journal of molecular sciences · 2026Review
- High Prevalence and Clinical Impact of Fibromyalgia in Functional Motor Disorder.Movement disorders clinical practice · 2026Article
- The Effect of Intravenous Lidocaine Treatment on Sleep and Quality of Life in Fibromyalgia: An Observational Study.Journal of clinical medicine · 2026Article
- Effect of different types of exercise in fibromyalgia syndrome: a network meta-analysis.BMC sports science, medicine & rehabilitation · 2026Article
- Central Sensitization and Nociplastic Pain: Shared Mechanisms in Fibromyalgia, Osteoarthritis, and Inflammatory Arthritis.Journal of pain research · 2026Review
- Prevalence and predictors of fibromyalgia symptoms in an academic setting: a cross-sectional study.BMC rheumatology · 2025Article
- Prickly Pear and Fibromyalgia: A Conceptual Protocol for Plant-Based Symptom Management.Nutrients · 2025Review
- Characterisation of the Oral Microbiome in Women With Fibromyalgia: An Observational Case-Control Study.European journal of pain (London, England) · 2025Observational
- Exploiting allosteric modulation: a new frontier for precision medicine.Molecular biology reports · 2025Review
- Exploring Chronic Pain in Hemodialysis Patients: An Observational Study Based on the New IASP Classification for ICD-11.Pain and therapy · 2025Article
- A Comprehensive Analysis of Fibromyalgia and the Role of the Endogenous Opioid System.Biomedicines · 2025Review
- Incident gabapentin prescribing associated with opioid and benzodiazepine/Z-drug prescribing - a population-based longitudinal study in primary care.Frontiers in pharmacology · 2025Article
- Evolution of the Quality of Life of Long-Term Fibromyalgia Users of Millimeter Wave-Based Neuromodulation: A Real-World Retrospective Study.Journal of pain research · 2025Article
- Pain Management in Fibromyalgia: Evaluating the Roles of Pregabalin, Duloxetine, and Milnacipran.Cureus · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewFibromyalgia Syndrome (FMS) is a complex chronic pain condition characterized by widespread musculoskeletal pain and numerous other debilitating symptoms. The purpose of this review is to provide a comprehensive overview, based on everyday clinical practice, of the drugs presently employed in the treatment of FMS. RECENT
findingsThe treatment of FMS is based on a multimodal approach, with pharmacologic treatment being an essential pillar. The drugs used include tricyclic antidepressants, serotonin and noradrenaline reuptake inhibitors, other antidepressants, anticonvulsants, myorelaxants, and analgesics. The effectiveness of these medications varies, and the choice of drug often depends on the specific symptoms presented by the patient. Many drugs tend to either address only some domains of the complex FMS symptomatology or have a limited effect on pain. Each treatment option comes with potential side effects and risks that necessitate careful consideration. It may be beneficial to divide patients into clinical subpopulations, such as FMS with comorbid depression, for more effective treatment. Despite the complexities and challenges, the pharmacological treatment remains a crucial part for the management of FMS. This review aims to guide clinicians in prescribing pharmacological treatment to individuals with FMS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.